444002-55-5

Upstream product

• 6332-77-0 N-(4-nitrophenyl)ethylenediamine 
• 867166-76-5 C₁₇H₂₅N₃O₆ 
• 636-98-6 p-nitrobenzene iodide 
• 76003-29-7 4-(t-butyloxycarbonyl)piperazin-2-one 
• 867166-73-2 1-(4-nitrophenyl)piperazin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 867166-71-0 {tert-butoxycarbonyl-[2-(4-nitrophenylamino)-ethyl]-amino}-acetic acid 

Downstream Products

• 867166-74-3 1-(4-nitrophenyl)-piperazine-2-one trifluoroacetic acid salt 
• 867166-73-2 1-(4-nitrophenyl)piperazin-2-one 

Relevant academic research and scientific papers

TANK-BINDING KINASE INHIBITOR COMPOUNDS

Compounds having the following formula (I) and methods of their use and preparation are disclosed:

IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Compounds of formula I that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula I and therapeutically acceptable salts, prodrugs and salts of prodrugs thereof, wherein X is CH or N; A1 is R1, OR1. NHR1, N(R1)2, NHC(O)R1, NHC(O)NHR1, NHC(O)N(R1)2, NHC(O)OR1, C(O)NHR1, C(O)N(R1)2, C=NOR1, or C(NH2)NOC(O)R1;

2-PROPENE-1-ONES AS HSP 70 INDUCERS

The present invention relates to novel compounds of 2-propene-1-one series, of general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, wherein R5, R6, Q and Y are as defined in the specification. The present invention also relates to a process for preparing such compounds, compositions containing such compounds, and use of such compound and composition in medicine. The compounds of the general formula (I) induce HSP-70 and are useful for the treatment of diseases accompanying pathological stress in a living mammalian organism, including a human being, such as stroke, myocardial infarction, inflammatory disorder, hepatotoxicity, sepsis, diseases of viral origin, allograft rejection, tumourous diseases, gastric mucosal damage, brain haemorrhage, endothelial dysfunctions, diabetic complications, neuro-degenerative diseases, post-traumatic neuronal damage, acute renal failure, glaucoma and aging related skin degeneration.

Phenyl derivatives

Novel compounds of the formula I in which W, X, Y, T, R1 and R2 are as defined in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.